The contributors to this Board probably watch Cortex more closely than anyone outside of Cortex employees. There has not been any substantive reason for the price to move up strongly--the financing extended lifespan, and staunched the bleeding. But the task remains the same: They have to produce a tangible achievement:
It will probably be a RD deal, with or without SA ( I have no idea which--so long as it doesn't include CX-1739)
Much less likely: ADHD/CX-1739 or neurodegeneration/high-impact deal
OR--positive SA data: And I am not counting on that after all this time, given the evidence that the apnea endpoint fluctuates a lot even without any intervention
It will require one of these markers of progress, not just a longer runway, for significant change in valuation.
NeuroInvestment
Market Data 
Markets 
